Volume 6 Issue 4
Jul.  2015
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2015  >  6(4): 245-248, 267
Tu Zhiyue, Sun Liying, Zhu Zhijun, et al. Clinical study of de novo hepatitis B virus infection after pediatric living liver transplantation[J]. ORGAN TRANSPLANTATION, 2015, 6(4): 245-248, 267. doi: 10.3969/j.issn.1674-7445.2015.04.008
Citation: Tu Zhiyue, Sun Liying, Zhu Zhijun, et al. Clinical study of de novo hepatitis B virus infection after pediatric living liver transplantation[J]. ORGAN TRANSPLANTATION, 2015, 6(4): 245-248, 267. doi: 10.3969/j.issn.1674-7445.2015.04.008
shu

Clinical study of de novo hepatitis B virus infection after pediatric living liver transplantation

doi: 10.3969/j.issn.1674-7445.2015.04.008

  • Tianjin Medical University, Tianjin 300070, China

More Information
  • Corresponding author: Sun Liying, Email:sunxlx@outlook.com
  • Received Date: 2015-05-14
    Available Online: 2021-01-19
  • Publish Date: 2015-07-15
    Abstract
  •   Objective  To investigate the clinical characteristics, prevention and treatment strategy of de novo hepatitis B virus (HBV) infection after pediatric living liver transplantation.  Methods  In total, 106 pediatric recipients undergoing living liver transplantation in Organ Transplantation Center of Affiliated Beijing Friendship Hospital of Capital Medical University and Organ Transplantation Center of Tianjin First Center Hospital from July 2010 to July 2014 were enrolled in this study. All surgeries were performed by the same surgical team. According to preoperative test outcomes of donor HBV serological markers, all recipients were divided into the positive (n=45) and negative (n=61) antibody to hepatitis B core antigen (anti-HBc) donor liver groups(positive group and negative group), and the prevalence of de novo HBV infection was compared between two groups. The risk factors of de novo HBV infection in the positive group were analyzed to elucidate the clinical characteristics of de novo HBV infection in affected children.  Results  The incidences of de novo HBV infection in positive and negative group were 18%(8/45) and 2%(1/61) respectively. The risk factors of de novo HBV infection in recipients with positive anti-HBc were negative anti-HBs before transplantation and absence of antiviral therapy post-transplantation in recipients (both in P < 0.05). The median interval between time of onset and time of liver transplantation was 12 months (8-48 months). Seven cases were treated with lamivudine and the remaining two cases were left untreated. All nine recipients survived.  Conclusions  Application of positive anti-HBc donor liver have a risk of HBV infection in recipients after pediatric liver transplantation. Absence of postoperative nucleoside analogue therapy and negative anti-HBs before transplantation acts as risk factors of de novo HBV infection in the recipients with positive anti-HBc donor liver. After liver transplantation, nucleoside analogue therapy is recommended for the pediatric recipients with positive anti-HBc donor liver to prevent the incidence of de novo HBV infection. Besides, hepatitis B vaccine should be administered prior to liver transplantation.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts:a systematic analysis[J]. Clin Transplant, 2011, 25(3):E243-E249. doi: 10.1111/ctr.2011.25.issue-3
    [2]
    Cholongitas E, Ppatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors:a systematic review[J]. Hepatol, 2010, 52(2):272-279. doi: 10.1016/j.jhep.2009.11.009
    [3]
    Liang X, Bi S, Yang W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China[J]. Infect Dis, 2009, 200(1):39-47. doi: 10.1086/599173
    [4]
    Lo CM, Fan ST, Liu CL, et al. Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation[J]. Liver Transpl, 2003, 9(8):827-832. doi: 10.1053/jlts.2003.50115
    [5]
    Chen YS, Wang CC, de Villa VH, et al.Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors[J]. Clin Transplant, 2002, 16(6):405-409. doi: 10.1034/j.1399-0012.2002.01133.x
    [6]
    Angelico M, Nardi A, Marianelli T, et al. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival:evidence from the Liver Match cohort study[J]. Hepatol, 2013, 58(4):715-723. doi: 10.1016/j.jhep.2012.11.025
    [7]
    Xi ZF, Xia Q, Zhang JJ, et al. De novo hepatitis B virus infection from anti-HBc positive donors in pediatric living donor liver transplantation[J]. Dig Dis, 2013, 14(8):439-445. doi: 10.1111/cdd.2013.14.issue-8
    [8]
    Sun LY, Yang YS, Zhu ZJ, et al. Outcomes in children with biliary atresia following liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2013, 12(2):143-148. doi: 10.1016/S1499-3872(13)60023-5
    [9]
    Scuderi V, Ceriello A, Santaniello W, et al. Hepatitis B prophylaxis in hepatitis B-negative recipients transplanted with donor grafts positive for hepatitis B core antibodies[J]. Transplant Proc, 2011, 43(1):271-273. doi: 10.1016/j.transproceed.2010.09.100
    [10]
    Saab S, Waterman B, Chi AC, et al. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors:a systematic review[J]. Liver Transpl, 2010, 16(3):300-307. http://www.ncbi.nlm.nih.gov/pubmed/20209589
    [11]
    Rao W, Man Xie, Tao Yang, et al. Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation[J]. World J Gastroenterol, 2014, 20(36):13159-13166. doi: 10.3748/wjg.v20.i36.13159
    [12]
    Katsurada A, Marusawa H, Uemoto S, et al.Circulating antibody to hepatitis B core antigen does NOT always reflect the latent hepatitis B virus infection in the liver tissue[J]. Hepatol Res, 2003, 25(2):105-114. doi: 10.1016/S1386-6346(02)00215-2
    [13]
    Su WJ, Ho MC, Ni YH, et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection[J]. Pediatr Gastroenterol Nutr, 2009, 48(2):203-208. doi: 10.1097/MPG.0b013e3181819ad4
    [14]
    Chang SH, Suh KS, Yi NJ, et al. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation[J]. Hepatology, 2003, 37(6):1329-1334. doi: 10.1053/jhep.2003.50227
    [15]
    Park JB, Kwon CH, Lee KW, et al. Hepatitis B virus vaccine switch program for prevention of de novo hepatitis B virus infection in pediatric patients[J]. Transpl Int, 2008, 21(4):346-352. doi: 10.1111/tri.2008.21.issue-4
    [16]
    Dehghani SM, Shakiba MA, Ziaeyan M, et al. Vaccination status in pediatric liver transplant candidates[J]. Pediatr Transplant, 2009, 13(7):820-822. doi: 10.1111/ptr.2009.13.issue-7
    [17]
    Ohno Y, Mita A, Ikegami T, et al. Successful active immunization using a hepatitis B virus vaccination protocol for a recipient with hepatitis B core antibody-positive liver graft.[J].Transplant Proc, 2014, 46(3):721-725. doi: 10.1016/j.transproceed.2013.12.005
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (106) PDF downloads(6) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return